PLA2G4C

Across TCGA pan-cancer cohorts, PLA2G4C Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PLA2G4C data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PLA2G4C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLA2G4C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, THYM, and DLBC are the cancer types where PLA2G4C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.446	0.925	<.001	36	view →
THYM	OS	Median	All	0.604	0.975	<.001	27	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	18	view →
COAD	DFS	Median	II,III,IV	0.126	0.747	<.001	13	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
LUSC	OS	Median	All	0.173	0.724	.012	9	view →
LIHC	DFS	Median	II,III,IV	0.070	0.429	.001	9	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	DFS	Median	All	0.953	0.828	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PLA2G4C–BRCA (OS)

Open the BRCA breakdown →